Lutein / GSTA1 Cancer Research Results

Lut, Lutein: Click to Expand ⟱
Features:

Lutein (L; xanthophyll carotenoid) — dietary pigment concentrated in the macula (with zeaxanthin) forming macular pigment; sourced from leafy greens (kale/spinach), corn, egg yolk, and supplements (often paired with zeaxanthin).

Primary mechanisms (conceptual rank):
1) Blue-light filtering + macular pigment optical protection
2) Antioxidant / anti–lipid-peroxidation (↓ ROS burden in retina and other tissues)
3) Anti-inflammatory signaling modulation (e.g., NF-κB tone; context-dependent)
4) Secondary signaling effects in cancer models (PI3K/AKT, MAPK, apoptosis; high concentration only)

Bioavailability / PK relevance: Fat-soluble; absorption improves with dietary fat; plasma lutein rises dose-dependently with supplementation and accumulates in retina (macular pigment). Long-term dosing (weeks–months) is typical for tissue effects.

In-vitro vs oral exposure: Most direct anti-cancer cytotoxicity requires supra-physiologic concentrations (high concentration only); clinical relevance is strongest for eye outcomes (AMD risk progression).

Clinical evidence status: Supported within AREDS2-style formulations for reducing progression risk in intermediate → advanced AMD (eye-specific benefit); cancer evidence remains preclinical.

Lutein
-Kale, spinach, parsley, corn, egg yolks, peas
-Breast cancer: Inverse correlation with dietary intake
- Potent antioxidant, scavenges ROS (reactive oxygen species)
-Downregulates NF-κB and other inflammatory pathways
-Promotes apoptosis in cancer cells
-inhibits angiogenesis

Lutein — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↔ / ↓ (context-dependent; high concentration only for cytotoxicity) ↓ (primary) P/R Antioxidant buffering Core physiologic role is antioxidant protection (notably retina); tumor redox effects vary and are often concentration/model dependent.
2 NRF2 antioxidant-response program ↔ / ↑ (context-dependent) ↑ R/G Stress-defense upshift Typically consistent with cytoprotection; in tumors, NRF2 upshift can be double-edged (potential resistance context).
3 NF-κB / inflammatory cytokine programs ↓ (model-dependent) ↓ R/G Anti-inflammatory signaling Relevant to systemic low-grade inflammation framing in AMD; cancer relevance varies by tumor microenvironment context.
4 HIF-1α / angiogenesis coupling ↓ (model-dependent; high concentration only) ↔ G Reduced hypoxia-adaptation signaling (preclinical) Reported in some preclinical models; not a dominant clinically validated axis for lutein.
5 PI3K/AKT and MAPK (ERK/JNK) ↓ or ↔ (model-dependent; high concentration only) ↔ R/G Secondary survival-signaling modulation Observed in vitro with extract/compound exposure; not established at typical supplement systemic exposure.
6 Apoptosis (caspases; mitochondrial) ↑ (high concentration only) ↔ R/G Experimental cytotoxicity Anti-cancer apoptosis effects usually require supra-physiologic exposure vs oral supplementation.
7 Ferroptosis susceptibility (PUFA/lipid ROS context) ↔ (limited; context-dependent) ↔ R/G Not a canonical lutein axis Lutein is more classically antioxidant; ferroptosis linkage is not central or consistently demonstrated.
8 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized dominant mechanism for lutein.
9 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Oncology concentration gap Strongest human data are eye-related (AREDS2); most direct oncology mechanisms rely on higher in-vitro exposure than typical systemic levels.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr


Lutein — AD relevance: Lutein preferentially accumulates in the brain and has been linked to neural efficiency and modest cognitive performance effects in older adults; mechanisms emphasize antioxidant/anti-inflammatory protection and membrane/synaptic support. Evidence is supportive but not disease-modifying.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↓ ROS; membrane protection)
2) ↓ Neuroinflammation (cytokine/NF-κB tone; context-dependent)
3) ↑ Neural efficiency / connectivity signals (human MRI/fMRI supplementation studies)
4) Secondary Aβ/tau pathway effects (preclinical emphasis)

Bioavailability / PK relevance: Chronic intake increases circulating lutein and is associated with higher macular pigment (used as a biomarker linked to brain lutein status). Effects are generally time-dependent (months).

Clinical evidence status: Small RCTs and imaging trials in older adults show signals for neural efficiency/cognition; AD-specific clinical evidence remains limited.

Lutein — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↓ P/R Reduced oxidative burden Central neuroprotective rationale; aligns with membrane and mitochondrial resilience concepts.
2 Neuroinflammation (NF-κB, cytokine tone) ↓ (context-dependent) R/G Lower inflammatory stress Often framed as systemic/low-grade inflammation modulation; human mechanistic specificity varies.
3 Neural efficiency / network connectivity (functional imaging outcomes) ↑ G More efficient task-related activation Randomized trials report changes in brain function metrics and some cognitive measures with L (± Z) supplementation.
4 Synaptic membrane support (lipid microdomain stability) ↑ (supportive) G Signal transduction support Mechanistic framing consistent with carotenoid localization in neural tissue; largely supportive/inferential.
5 NRF2 axis ↔ / ↑ (adaptive; context-dependent) R/G Stress-defense regulation Potential secondary antioxidant-response involvement; not always directly measured in human trials.
6 Aβ / tau-associated pathology ↔ / ↓ (preclinical) G Reduced pathological burden (hypothesis) Evidence is stronger in models than in AD biomarker-confirmed human studies.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ P/R No primary role Not a canonical lutein mechanism; include only if model explicitly measures Ca²⁺/excitotoxic endpoints.
8 Clinical Translation Constraint ↓ (constraint) — Supportive, not disease-modifying Signals in small RCTs/imaging studies; effect sizes modest and depend on duration, baseline status, and co-nutrients (e.g., zeaxanthin).

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
GSTA1, Glutathione S-Transferase A1: Click to Expand ⟱
Source:
Type:
GSTA1 belongs to the glutathione S-transferase (GST) superfamily of enzymes. These enzymes catalyze the conjugation of glutathione (GSH) to a variety of electrophilic substrates, thereby aiding in their detoxification.
By facilitating the detoxification of reactive metabolites, carcinogens, and drugs, GSTA1 helps protect cells against oxidative stress and chemical-induced damage.
In tumor cells, upregulation of GSTA1 may be a defensive response to increased oxidative stress. While this can protect normal cells, in a tumor setting, enhanced detoxification may allow cancer cells to survive in a hostile microenvironment.
Elevated levels of GSTA1 have been linked to resistance to chemotherapy. As GSTA1 helps metabolize and clear chemotherapeutic agents, its overexpression in tumors can contribute to treatment resistance
-GSTA1 expression levels are being evaluated as a prognostic marker. In some studies, its overexpression has correlated with aggressive tumor behavior, higher rates of recurrence, and reduced overall survival.
Scientific Papers found: Click to Expand⟱
4231- Lut,    Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application
- Review, AD, NA
*PSD95↑, *BDNF↑, *SOD↑, *GSTA1↑, *MDA↑, *Casp3↓, *Mood↑, *antiOx↑, *Apoptosis↓, *Inflam↓, *ER Stress↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSTA1↑, 1,   MDA↑, 1,   SOD↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Casp3↓, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,   PSD95↑, 1,  

Functional Outcomes ⓘ

Mood↑, 1,  
Total Targets: 11

Scientific Paper Hit Count for: GSTA1, Glutathione S-Transferase A1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:349  Target#:1091  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page